Merck (MRK) Non-Current Deferred Tax Liability (2009 - 2026)

Merck (MRK) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with $1.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability changed 0.42% year-over-year to $1.4 billion in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 0.42% change from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 52.91% from the prior year.
• Non-Current Deferred Tax Liability was $1.4 billion for Q2 2026 at Merck, down from $1.5 billion in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $4.3 billion in Q4 2022 and troughed at $864.0 million in Q3 2024.
• A 5-year average of $1.9 billion and a median of $1.4 billion in 2025 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability surged 155.07% in 2022 and tumbled 66.51% in 2023, its largest moves.
• Over 5 years, Non-Current Deferred Tax Liability stood at $4.3 billion in 2022, then plunged by 31.32% to $3.0 billion in 2023, then grew by 3.31% to $3.1 billion in 2024, then sank by 52.91% to $1.4 billion in 2025, then dropped by 0.42% to $1.4 billion in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $1.4 billion (Q2 2026), $1.5 billion (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.